Ask AI
ProCE Banner Activity

MK-8591A-051 Post Hoc Analysis: Switch From Complex ART to DOR/ISL in People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

In this post hoc analysis of an open-label phase III study, switching to DOR/ISL from a complex ART regimen (≥2 pills/day or boosted PI or NNRTI + ≥1 drug from a non-NRTI class) maintained HIV-1 RNA <50 copies/mL in >96% of participants through 48 weeks.

Released: August 05, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the International AIDS Society.

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

International AIDS Society

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions